Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

@article{Lai2006EntecavirVL,
  title={Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.},
  author={Ching-lung Lai and Daniel Shouval and A S Lok and Ting-Tsung Chang and Hugo Cheinquer and Zachary Goodman and Deborah Dehertogh and Richard B Wilber and Richard C. Zink and A. Cross and R. J. Colonno and Lori Fernandes},
  journal={The New England journal of medicine},
  year={2006},
  volume={354 10},
  pages={1011-20}
}
BACKGROUND Entecavir is a potent and selective antiviral agent that has demonstrated efficacy in phase 2 studies in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. METHODS In this phase 3, double-blind trial, we randomly assigned 648 patients with HBeAg-negative chronic hepatitis B who had not previously been treated with a nucleoside analogue to receive 0.5 mg of entecavir or 100 mg of lamivudine once daily for a minimum of 52 weeks. The primary efficacy end point… CONTINUE READING
Highly Influential
This paper has highly influenced 23 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 448 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Similar Papers

Loading similar papers…